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O B J E C T I V E S The major aim of this study is to test the hypothesis that stress cardiac magnetic
resonance (CMR) imaging can provide robust prognostic value in women presenting with suspected
ischemia, to the same extent as in men.
B A C KG ROUND Compelling evidence indicates that women with coronary artery disease (CAD)
experience worse outcomes than men owing to a lack of early diagnosis and management. Numerous
clinical studies have shown that stress CMR detects evidence of myocardial ischemia and infarction at
high accuracy. Compared to nuclear scintigraphy, CMR is free of ionizing radiation, has high spatial
resolution for imaging small hearts, and overcomes breast attenuation artifacts, which are substantial
advantages when imaging women for CAD.
METHOD S We performed stress CMR in 405 patients (168 women, mean age 58  14 years)
referred for ischemia assessment. CMR techniques included cine cardiac function, perfusion imaging
during vasodilating stress, and late gadolinium enhancement imaging. All patients were followed for
major adverse cardiac events (MACE).
R E S U L T S At a median follow-up of 30 months, MACE occurred in 36 patients (9%) including 21
cardiac deaths and 15 acute myocardial infarctions. In women, CMR evidence of ischemia (ISCHEMIA)
demonstrated strong association with MACE (unadjusted hazard ratio: 49.9, p  0.0001). While women
with ISCHEMIA() had an annual MACE rate of 15%, women with ISCHEMIA() had very low annual
MACE rate (0.3%), which was not statistically different from the low annual MACE rate in men with
ISCHEMIA() (1.1%). CMR myocardial ischemia score was the strongest multivariable predictor of MACE
in this cohort, for both women and men, indicating robust cardiac prognostication regardless of sex.
CONC L U S I O N S In addition to avoiding exposure to ionizing radiation, stress CMR myocardial
perfusion imaging is an effective and robust risk-stratifying tool for patients of either sex presenting with
possible ischemia. (J Am Coll Cardiol Img 2011;4:850–61) © 2011 by the American College of
Cardiology Foundation
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851espite the advent of medical therapy and
improvement in patient prognosis in the
past decades, women with coronary artery
disease (CAD) continue to experience
higher morbidity and mortality than men indepen-
dent of age (1). Current noninvasive methods have
reduced diagnostic accuracy in women leading to
delayed CAD recognition and management, which
have been associated with the observed adverse
outcomes. Noninvasive detection of CAD in
women is challenged by atypical symptoms, breast
attenuation artifacts, small-sized heart, and age-
related comorbidities that limit exercise tolerance
(2,3). Cardiac magnetic resonance (CMR) provides
a radiation-free assessment of cardiac function,
myocardial ischemia, and infarction at high spatial
resolution and tissue contrast. Recent studies have
shown that stress CMR provides effective cardiac
prognostication in patients with chest pain (4,5),
but it is unclear whether this robust association with
clinical events can be extended to a similar degree to
patients of either sex. Our study aimed to test the
hypothesis that stress CMR myocardial perfusion
imaging for ischemia provides robust cardiac prog-
nostication in women in a consecutive patient
cohort referred for ischemia assessment.
M E T H O D S
Patient population. We prospectively studied 424
atients (177 women) who were referred to undergo
asodilator stress CMR for assessment of myocar-
ial ischemia. Detailed medical history was taken
mmediately before CMR study. A history of dys-
ipidemia, family history of premature CAD,
hronic hypertension, and diabetes were as defined
y recent guidelines (6–8). Significant tobacco use
as defined as a 10 pack-years of cigarette smok-
ng or any current use of tobacco. Patients were
xcluded from undergoing CMR in any of the
ollowing conditions: 1) acute myocardial infarction
MI) or unstable angina; 2) decompensated heart
ailure; 3) known infiltrative or hypertrophic car-
iomyopathy or myocarditis; 4) hemodynamic in-
tability; 5) absolute contraindication to vasodilator
se; 6) severe claustrophobia despite use of seda-
ives; and 7) presence of metallic hazards. Since
une 2008, patients with an estimated glomerular
ltration rate of 30 ml/min/1.73 m2 within 30
days before CMR were also excluded. The CMR
results from the initial 254 patients of the current
study cohort were analyzed and reported in another
publication (9). All patients provided informed cconsent at the time of the CMR, and our institu-
tional ethics committee approved the study for
clinical follow-up.
Vasodilating stress CMR imaging protocol. All pa-
tients were studied while in the supine position
either in a 1.5-T scanner (Signa CV/i, GE Health-
care, Milwaukee, Wisconsin) with an 8- or 12-
element cardiac phased-array coil (n  381) or in a
3.0-T system (Magnetom TIM TRIO, Siemens,
Erlangen, Germany) (n  43) with a 16-element
phased-array coil. Patients were asked to refrain
from caffeine for 24 h and maintain fasting for 4 h
before CMR. CMR myocardial perfusion
imaging was acquired using a saturation-
prepared T1-weighted fast gradient-echo
sequence (typical parameters included
repetition time 6 ms, echo time 2.3
ms, field of view 34 to 38 cm, matrix size
160  128 yielding in-plane spatial
esolution 2.1  2.7 mm to 2.4  3.0
m, 8-mm slice thickness, parallel imag-
ng with an acceleration factor of 2, tem-
oral resolution 100 to 120 ms with 4 to
slices acquired every R-R interval, and
ime after saturation pulse of 123 ms)
uring a first-pass bolus of gadolinium–
iethylenetriamine pentaacetic acid
Magnevist, Bayer, Wayne, New Jersey)
nfusion (0.075 to 0.1 mmol/kg at 4 to 5
l/s) at peak vasodilation. A notched-
aturation prepared pulse sequence with
n echoplanar read out (echo train length
) was used in the early studies. Adenosine
as infused intravenously at 140 g/kg/
in over 4 to 5 min and CMR myocardial
erfusion was acquired during the last
inute. Adenosine (Adenocard, Astellas
harma US, Deerfield, Illinois) was used
s the stress agent in the majority of cases
n  394, 92%), but dipyridamole (Per-
antin, Boehringer Ingelheim, Ingelheim
m Rhein, Germany) was used in 33 cases
8%) as requested by the referring physicians. Di-
yridamole was injected at 0.56 mg/kg over 4 min
ith a possible addition of 0.28 mg/kg within a
-min interval after the first injection to achieve a
0% heart rate increase from baseline. When dipyr-
damole was used, stress CMR myocardial perfu-
ion imaging was acquired when the target heart
ate was achieved or at 3 min after dipyridamole
njection. Typically 4 to 5 short-axis locations were
maged every heartbeat for 50 to 60 heartbeats to
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852ular (LV) size and function were acquired using
cine steady-state free precession (typical repetition
time 3.4 ms, echo time 1.2 ms, temporal resolution
40 to 50 ms, in-plane spatial resolution 1.5 to 1.8
mm and 1.8 to 2.1 mm, depending on the field of
view) in a stack of parallel short-axis planes (8 mm
thick without spacing) and 3 radial long-axis planes.
At 10 to 20 min after injection of a cumulative 0.15
to 0.2 mmol/kg of gadolinium, we performed late
gadolinium enhancement (LGE) imaging as previ-
ously described (10) in short-axis and radial long-
axis locations matching cine imaging. All patients
were monitored by electrocardiography (ECG),
sphygmomanometry, and pulse oximetry during the
CMR study, and 12-lead ECG was performed
before and after CMR.
CMR image analysis. All images were analyzed using
pecialized software (QMass MR version 7.1, Me-
is Medical Imaging Systems, Leiden, the Nether-
ands) blinded to patient outcome. We manually
raced epicardial and endocardial borders of short-
xis cine locations at end-systole and end-diastole
o determine the LV ejection fraction (LVEF), LV
nd-diastolic volume index (LVEDVi), LV end-
ystolic volume index (LVESVi), and LV myocar-
ial mass (11,12). LVEF was measured by the
tandard Simpson rule using summation of short-
xis locations. Segmental wall motion abnormality
as graded as present only if it was concordant on
oth the short-axis and the radial long-axis views.
MR myocardial perfusion images were analyzed
y a consensus of 2 experienced cardiologists with
ualitative interpretation of stress CMR myocardial
erfusion and LGE images (side-by-side display)
linded to clinical information, patient outcome, or
ine LV function. Specifically, a stress perfusion
efect was considered to be abnormal only if it
ulfilled the following criteria, as reported previ-
usly by Gerber et al. (13): 1) persistence of defect
eyond peak myocardial contrast enhancement;
) defect did not exist before arrival of first-pass
ontrast; and 3) segmental locations that conformed
o 1 or more coronary territories according to the
merican Heart Association/American College of
ardiology nomenclature. Peak myocardial en-
ancement was defined as the last frame of progres-
ive signal enhancement during first-pass transit of
adolinium–diethylenetriamine pentaacetic acid.
ollowing the American Heart Association/
merican College of Cardiology 17-segment no-
enclature (14), any segmental perfusion was in-
erpreted as normal or abnormal. Each segmental
erfusion was scored based on the subendocardial dxtent of any perfusion defect (0, no defect; 1,
50%; 2,50%). Because we were unable to assess
he apical cap (segment number 17) due to the
hort-axis acquisition, perfusion score of this seg-
ent was treated as missing. A perfusion defect was
onsidered significant only if it persisted beyond
eak myocardial enhancement. Evidence of isch-
mia (ISCHEMIA) was defined by any segmental
tress perfusion defect without any matching seg-
ental LGE. Myocardial extent of ischemia
ISCH-SCORE) (maximal score of 32) was calcu-
ated by summing up the segmental perfusion score
rom stress myocardial perfusion imaging in seg-
ents without LGE. Any segment with a stress
erfusion defect with LGE present in the matching
egment was excluded from the calculation of
SCH-SCORE. Intraobserver and interobserver
ariability for identifying ISCHEMIA were as-
essed in 38 randomly selected studies. Intraob-
erver and interobserver kappa values for ISCH-
MIA present (ISCHEMIA []) were 0.82 and
.87, respectively (95% confidence interval: 0.61 to
.0 and 0.69 to 1.0, respectively). Intraobserver and
nterobserver concordance correlation coefficients of
SCH-SCORE were 0.85 and 0.88, respectively.
nfarct mass was quantified using a semiautomated
lgorithm that defined LGE as any region with a
ignal intensity 2 SDs above the mean signal
ntensity of a remote myocardial region (10).
Invasive coronary angiography. Invasive coronary
ngiography after CMR was performed at the
iscretion of the attending physician. Coronary
ngiography was interpreted by the consensus of 2
xperienced invasive cardiologists who reported any
evere epicardial coronary stenosis, defined as
70% narrowing of luminal diameter of any of the
major epicardial arteries or 50% narrowing of
he left main coronary artery from 2 orthogonal
iews (15).
Patient follow-up for clinical events. Patient
ollow-up was performed at least 6 months after the
MR. With institutional approval, we first con-
acted the patients by mailed questionnaire and
elephone calls. If contact was unsuccessful, we then
hecked our electronic medical records, called each
atient’s primary care physician, and checked vital
tatus using the Social Security Death Index (16).
e defined major adverse cardiac events (MACE)
uring follow-up as cardiac death or new acute MI.
ardiac death refers to any death preceded by acute
I, acute or exacerbation of cardiac failure, or
ocumented fatal arrhythmia. Any unexpected
eath without a noncardiac cause was also consid-
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853ered cardiac. New MI was defined by symptoms
consistent with acute MI and elevation of peak
serum troponins to twice normal or higher in a
temporal pattern consistent with myocardial injury.
When a patient experienced 1 event, the first
event was chosen. Patients who died of noncardiac
causes were censored on the day of death. Patients
who underwent early coronary revascularization (ei-
ther percutaneous or surgical revascularization
within the first 60 days after CMR) were not
censored. Rather, early coronary revascularization
was coded as a binary variable and used in all
univariable and multivariable analyses. CMR results
were provided to the referring physicians on the day
that CMR was performed.
Statistical analyses. Baseline patient characteristics
tratified by sex are displayed in Table 1. In Table 1,
omparisons were made using the Fisher exact test
or binary variables and the student t test or Wil-
oxon rank-sum test for continuous variables.
aplan-Meier curves in either sex were generated
or MACE, stratified by ISCHEMIA and com-
ared by log-rank tests. We used the strongest set
f clinical variables and their respective regression
oefficients reported by Hachamovitch et al. (17) to
alculate a weighted clinical risk profile score
SCOREClinical). This SCOREClinical was calcu-
lated as reported by Hachamovitch et al. (17) but
modified by excluding variables of nuclear scintig-
raphy. The SCOREClinical was therefore calculated
s follows: (patient age in decades ·5.19)  (diabe-
es mellitus ·3.88)  (coronary revascularization
ithin 60 days after CMR·4.51)  (dyspnea as a
resenting symptom·5.47)  (resting heart rate per
0 beats · 2.88)  (peak heart rate per 10
eats ·1.42)  (ECG score·1.95), whereas ECG
core was derived as follows: (any heart block·0.628) 
LV hypertrophy voltage with repolarization ab-
ormality ·0.724)  (presence of premature ven-
ricular beat · 0.832)  (nonspecific ST-T
bnormality ·0.331).
We used Cox regression in univariable associa-
ion of clinical, ECG, and CMR variables with
ACE. Considering all variables in Table 1, we
ought the best overall multivariable models for
ACE, separately in women and in men, by
tepwise forward selection using p 0.01 for model
ntry or stay. We also specifically tested for any
ffect modification by sex to the prognostic associ-
tion of ISCHEMIA with MACE by adding both
ex and an interaction term of sex and ISCHEMIA
nto a Cox model that associated ISCHEMIA withACE. In building any of the multivariable mod-ls, care was taken to follow the “10 MACE for
very variable” rule as much as possible to avoid
verfitting of any of the multivariable models. The
roportional hazard assumption was tested valid in
ach multivariable model by adding a time-
ependent interaction variable for every variable
ncluded in each best overall model. Because
COREClinical contained data collected during the
study follow-up period, it was treated as a time-
varying covariate in any multivariable model. We
therefore created a binary variable by dichotomizing
SCOREClinical at its median value from the whole
study cohort (median value  39.7). For any
multivariable model that included SCOREClinical,
e repeated the model with stratification to the
inary variable (obtained from dichotomizing
COREClinical). We determined the diagnostic
utility of ISCHEMIA in detecting coronary steno-
sis in patients who were referred to undergo coro-
nary angiography within 2 years after CMR. All
statistical analyses were performed with SAS ver-
sion 9.2 (SAS Institute, Cary, North Carolina).
R E S U L T S
Patient characteristics. We enrolled 424 consecutive
subjects referred to have vasodilator stress CMR for
assessment of ischemia. Nineteen enrolled patients
(4%, 8 of whom were women) were excluded from
study analysis due to the following reasons: scanner
failure (n  2), patient claustrophobia (n  8),
atient intolerance of pharmacological stress (n 
), and nondiagnostic image quality (n  2). Of
hese 19 excluded patients, 2 patients (11%) expe-
ienced cardiac death. The remaining 405 patients
96%) constituted the study cohort. Table 1 pro-
ides the demographic characteristics of the study
ohort stratified by sex. Compared with men,
omen had a lower prevalence of CAD based on
ewer histories of MI and coronary interventions,
ewer electrocardiographic Q waves, higher LVEF,
ower LVEDVi and LVESVi, less wall motion
bnormality, and fewer previous MIs by LGE.
Univariable analyses for MACE. Clinical follow-up by
either mailed questionnaire or telephone contact
was successful in all patients (median, 30 months;
range, 6 months to 6.9 years). No patient was
followed based only on Social Security Death Index.
During study follow-up, 36 patients (9%) experi-
enced MACE (21 cardiac deaths and 15 acute
MIs). Among them, 14 were women (7 cardiac
deaths and 7 acute MIs) and 22 were men (14
cardiac deaths and 8 acute MIs). Another 19
rven
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854patients (8 women, 11 men) died of noncardiac
causes and were censored on the day of death.
ISCHEMIA() was observed in 36 women (21%)
Table 1. Demographic Characteristics of the Study Cohort Strat
Clinical Variables
All Patients
(N  405)
Age, yrs 57 14
Body mass index, kg/m2 28 6
Hypertension 226 (56)
Diabetes 87 (22)
Hyperlipidemia 228 (57)
Tobacco use 60 (15)
Family Hx of CAD 104 (26)
SCOREClinical 39 9
Hx of MI 82 (20)
Hx of PCI 66 (16)
Hx of CABG 32 (8)
Early coronary revascularization 43 (11)
Medications
Aspirin 219 (55)
Beta-blocker 214 (53)
ACE inhibitor 166 (41)
Calcium channel blocker 68 (17)
Statins 221 (55)
Electrocardiography
Resting heart rate, beats/min 69 14
Sinus rhythm 374 (94)
QRS 120 ms 33 (8)
QTc 400 ms 9 (2.3)
Left bundle branch block 21(5.3)
Right bundle branch block 20(5.0)
LV hypertrophy 32 (8.0)
Signiﬁcant Q waves 56 (14)
Resting ST changes 51 (12.9)
Resting T-wave inversions 81 (20.5)
CMR variables
LVEF, % 57 13
LV mass index, g/m2 62 17
LVEDVi, ml/m2 86 26
LVESVi, ml/m2 39 24
Resting RWMA 101 (25.1)
LGE presence 119 (30)
LGE mass, per gram of tissue 4.4 11
% of LGE, per 10% of LV mass 3.3 8.3
Rest perfusion defect 53 (13)
Stress perfusion defect 126 (31)
ISCHEMIA() 109 (27)
ISCH-SCORE 1.3 3.0
ISCH-SCORE, ISCHEMIA() 5.0 4.0
Values shown are mean  SD or n (%).
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft;
ISCHEMIA()  evidence of ischemia present; ISCH-SCORE  myocardial exten
left ventricular end-diastolic volume index; LVEF  left ventricular ejection fract
RWMA  regional wall motion abnormality; PCI  percutaneous coronary inteand in 73 men (31%). Univariable associations ofclinical, electrocardiographic, and CMR variables
with MACE for the entire study cohort and strat-
ified by sex are presented in Table 2. Patient age,
by Sex
Women
(n  168)
Men
(n  237) p Value
58 14 57 14 0.56
28 7 28 5 0.86
103 (61) 123 (52) 0.07
31 (19) 56 (24) 0.22
83 (50) 145 (62) 0.05
19 (11) 41 (17) 0.12
48 (29) 56 (24) 0.35
39 10 40 9 0.77
24 (14) 58 (25) 0.05
13 (8) 53 (22) 0.0001
9 (5) 23 (10) 0.14
11 (6.6) 32 (14) 0.05
81 (49) 138 (60) 0.05
92 (55) 122 (52) 0.54
60 (36) 106 (45) 0.08
35 (21) 33 (14) 0.08
82 (50) 139 (59) 0.07
71 15 68 14 0.01
155 (93) 219 (94) 0.54
11 (7) 22 (10) 0.36
6 (3.6) 3 (1.3) 0.17
11 (6.6) 10 (4.3) 0.37
6 (3.6) 14 (6.0) 0.35
13 (7.7) 19 (8.2) 0.99
14 (8.3) 42 (18) 0.01
20 (12.1) 31 (13.5) 0.76
27 (16.4) 54 (23.5) 0.1
60 12 56 13 0.001
56 15 66 18 0.0001
79 21 92 27 0.0001
33 19 43 27 0.0001
25 (15) 76 (32.5) 0.0001
22 (13) 97 (41) 0.0001
1.8 7 6.2 13 0.0001
1.8 6.3 4.4 9.3 0.0001
16 (10) 37 (16) 0.09
39 (23) 87 (37) 0.005
36 (21) 73 (31) 0.05
0.9 2.2 1.6 3.5 0.05
4.3 2.9 5.3 4.4 0.15
 coronary artery disease; CMR  cardiac magnetic resonance; Hx  history;
schemia; LGE  late gadolinium enhancement; LV  left ventricular; LVEDVi 
VESVi  left ventricular end-systolic volume index; MI  myocardial infarction;
tion; SCOREClinical  clinical risk proﬁle score.iﬁed
CAD
t of i
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855CMR, SCOREClinical, and resting ST changes on
an electrocardiogram were the strongest clinical
predictors of MACE in the entire study cohort and
in either sex. Although LV end-systolic and end-
diastolic indexes, regional wall motion abnormality,
LGE presence, and abnormal CMR stress perfu-
sion by CMR all demonstrated strong univariable
association with MACE, ISCH-SCORE was the
strongest predictor by univariable analyses in the
entire cohort and in patients of either sex (likeli-
hood ratio [LR] chi-square test 62.12, 37.15, and
25.95; all p values  0.0001, in whole cohort,
women, and men, respectively). On average, the
hazard for MACE increased by 43% and 16% for
each unadjusted unit increase in ISCH-SCORE in
women and in men, respectively. ISCH-SCORE
was right skewed, and we performed a log-
transformation of ISCH-SCORE. The resultant
log-transformed ISCH-SCORE maintained robust
prognostic association with MACE (LR chi-square
Table 2. Univariable Prognostic Association With MACE Stratiﬁe
Clinical Characteristics
All Patients (N  405)
LR
Chi-Square
Test HR (95% CI)
Age, yrs 17.31 1.07 (1.03–1.1)
Female 0.01 0.98 (0.49–1.93)
Hypertension 12.13 5.4 (2.09–13.96)
Diabetes 4.23 2.05 (1.04–4.08)
Hyperlipidemia 3.38 2.04 (0.95–4.4)
Hx of MI 13.94 3.56 (1.82–6.93)
Hx of PCI 17.91 4.21 (2.16-8.18)
Hx of CABG 1.02 1.63 (0.63–4.21)
Early revascularization 19.05 4.74 (2.36–9.56)
SCOREClinical 26.51 1.11 (1.07–1.15)
Electrocardiographic ﬁndings
Left bundle branch block 6.31 3.37 (1.31–8.73)
Signiﬁcant Q waves 6.93 2.69 (1.29–5.61)
Resting ST changes 22.66 5.19 (2.63–10.22)
CMR results
LVEF, per 10% 22.58 0.95 (0.93–0.97)
LV mass index, g/m2 12.72 1.03 (1.01–1.04)
LVEDVi, per 10 ml/m2 20.84 1.02 (1.01–1.03)
LVESVi, per 10 ml/m2 28.25 1.02 (1.01–1.02)
Resting RWMA 28.31 7.06 (3.44–14.5)
LGE presence 10.29 3.08 (1.55–6.11)
LGE mass, per gram of tissue 4.73 1.02 (1.01–1.04)
LGE presence without Hx of MI 9.62 4.3 (1.7–10.79)
ISCHEMIA() 34.58 17.16 (6.65–44.25)
ISCH-SCORE 62.12 1.19 (1.14–1.24)
*Could not be determined due to low event.
CI  conﬁdence interval; HR  hazard ratio; LR  likelihood ratio; MACE  mtest  63.84, p  0.0001). ISCHEMIA() por-ended a 17-, 50-, and 11-fold unadjusted hazard
ncrease in MACE in the entire cohort, in women,
nd in men, respectively (LR chi-square test 34.58,
4.18, and 14.98; all p values  0.0001, respec-
ively). Among the 36 women who had ISCH-
MIA(), ISCH-SCORE was significantly
igher in those who experienced MACE (n  13)
han those who did not (n  23) (median ISCH-
CORE 5 vs. 3, p  0.04 by nonparametric
ilcoxon rank-sum test). LGE presence was a
trong predictor of MACE, but its association with
ACE appeared to be stronger in men than in
omen (LR chi-square test  6.63 vs. 3.88, p 
.01 vs. p  0.05, respectively).
Survival by Kaplan-Meier and event rates analysis.
Figure 1 shows the Kaplan-Meier curves stratified
by ISCHEMIA() in each sex. Figure 1 demon-
strated that ISCHEMIA() was associated with
reduced MACE-free survival and cardiac survival
for women and for men (all p values  0.001).
y Sex
Women (n  168) Men (n
alue
LR
Chi-Square
Test HR (95% CI) p Value
LR
Chi-Square
Test HR
.0001 7.95 1.07 (1.02–1.11) 0.005 9.16 1.06 (
.95 * * * * *
.0005 2.09 2.56 (0.71–9.19) 0.15 9.96 10.11 (
.05 0.95 1.78 (0.56–5.63) 0.33 4.43 3.21 (
.07 1.18 1.84 (0.62–5.48) 0.28 2.36 2.35 (
.0005 13.18 6.98 (2.45–19.91) 0.0005 4.05 2.44 (
.0001 3.34 3.29 (0.92–11.79) 0.07 14.59 5.56 (
.32 0.02 1.16 (0.15–8.89) 0.89 1.23 1.85 (
.0001 10.46 6.79 (2.13–21.66) 0.005 11.23 4.54 (
.0001 10.63 1.10 (1.04–1.16) 0.005 15.69 1.12 (
.01 0.06 1.28 (0.17–9.8) 0.81 10.38 6.12 (
.05 7.31 4.95 (1.55–15.8) 0.01 2.2 2.05 (
.0001 7.52 4.62 (1.57–13.79) 0.01 14.41 5.38 (
.0001 3.29 0.97 (0.9–1.01) 0.07 21.41 0.94 (
.0005 2.67 1.02 (0.99–1.05) 0.11 10.92 1.03 (
.0001 4.35 1.03 (1.01–1.06) 0.05 16.39 1.02 (
.0001 6.47 1.03 (1.01–1.05) 0.01 21.56 1.02 (
.0001 13.26 7.61 (2.55–22.67) 0.0005 16.06 7.94 (
.001 3.88 3.34 (1.01–11.1) 0.05 6.63 3.31 (
.05 0.9 1.03(0.97–1.08) 0.34 3.46 1.02 (
.005 0.88 2.76 (0.33–22.97) 0.34 8.41 5.74 (
.0001 14.18 49.9 (6.52–381.67) 0.0001 14.98 11.19 (
.0001 37.15 1.36 (1.23–1.5) 0.0001 25.95 1.14 (
adverse cardiac events; other abbreviations as in Table 1.d b
 237)
p V (95% CI) p Value
0 1.02–1.11) 0.005
0 *
0 2.35–43.51) 0.005
0 0.93–5.32) 0.07
0 0.79–6.99) 0.12
0 1.02–5.8) 0.05
0 2.31–13.42) 0.0005
0 0.62–5.17) 0.27
0 1.87–11.01) 0.001
0 1.06–1.19) 0.0001
0 2.03–18.44) 0.005
0 0.79–5.31) 0.14
0 2.56–12.83) 0.0001
0 0.91–0.96) 0.0001
0 1.01–1.05) 0.0005
0 1.01–1.03) 0.0001
0 1.01–1.03) 0.0001
0 2.89–21.86) 0.0001
0 1.33–8.24) 0.01
0 0.99–1.04) 0.06
0 1.76–18.69) 0.005
0 3.29–38.03) 0.0001
0 1.1–1.2) 0.0001Figure 2 shows the annual crude event rates of
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856MACE and cardiac death stratified by ISCH-
EMIA in either sex. Annual event rates of MACE
and cardiac death were significantly higher in pa-
tients with ISCHEMIA() in either sex. ISCH-
EMIA() was associated with very low annual
MACE in women (0.3%) and no women with
ISCHEMIA() experienced cardiac death during
follow-up (0%). On the contrary, ISCHEMIA()
in women was associated with high annual rates of
MACE and cardiac death (15.1% and 8.2%, respec-
Figure 1. Kaplan-Meier Curves for MACE and Cardiac Death
Kaplan-Meier curves for major adverse cardiac events (MACE) (A) an
Figure 2. Patient Annual Event Rates of MACE and of Cardiac D
Patient annual event rates of major adverse cardiac events (MACE)
Ischemia   evidence of ischemia absent; ischemia   evidence oftively). These annual MACE and cardiac death
rates in women were not different from the annual
event rates in the groups of men stratified by
ISCHEMIA. Figure 3 demonstrates a stress CMR
ase in a female patient.
Multivariable analyses for MACE. When sex, ISCH-
MIA, and an interaction term that described any
ffect modification of ISCHEMIA by sex were
ntered into a multivariable model for MACE, the
nteraction term did not demonstrate any prognos-
ardiac death (B) stratiﬁed by evidence of ischemia in each sex.
h
cardiac death, stratiﬁed by sex and evidence of ischemia.eat
and
ischemia present.
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857tic significance, suggesting against any evidence that
patient sex modified the strong association of
ISCHEMIA with MACE.
The best overall multivariable models for MACE
are summarized in Table 3. For the entire study
cohort, the strongest multivariable predictors of
MACE included ISCH-SCORE, ISCHEMIA,
and SCOREClinical. ISCH-SCORE was consis-
tently the strongest multivariable predictor for
MACE in each of the best overall multivariable
Table 3. Best Overall Multivariable Models by Stepwise Selectio
Variables
Adjusted LR Chi-Square
of the Variable
All patients (N  405)
ISCH-SCORE 7.13
ISCHEMIA 10.61
SCOREClinical 10.84
Women (n  168)
ISCH-SCORE 32.52
Early revascularization 12.14
Men (n  237)
ISCH-SCORE 17.52
SCOREClinical 14.95
Figure 3. Stress CMR Study From a 47-Year-Old Woman With a
Mid and apical short-axis views of the stress perfusion images show
inferoseptal, and inferolateral walls (red arrows) (A,C). Matching lat
dial myocardial infarction (MI) within the mid-inferior wall. CMR ISCHEMIA  evidence of ischemia; other abbreviations as in Table 1.models for MACE in all patients, women, and
men, respectively (Table 3, model LR chi-square
test  68.67, 37.71, and 30.81, all p  0.0001,
espectively). Along with early revascularization,
SCH-SCORE formed the best overall model for
ACE in women (LR chi-square test 12.14 and
2.52, p  0.0005 and p  0.0001, respectively).
long with SCOREClinical, ISCH-SCORE formed
he best overall model for MACE in men (LR
hi-square test  14.95 and 17.52, p  0.0001 and
All Patients, Women, and Men
(95% CI), p Value of the Variable
Model LR Chi-Square,
p Value
1.11 (1.03–1.19), p 0.008 68.67, p  0.0001
6.18 (2.07–18.51), p 0.001
1.08 (1.03–1.12), p 0.001
1.49 (1.31–1.69), p 0.0001 37.71, p  0.0001
9.09 (2.63–31.45), p 0.0005
1.17 (1.09–1.25), p 0.0001 30.81, p  0.0001
1.11 (1.05–1.17), p 0.0001
vious MI Referred for Assessment of Myocardial Ischemia
extensive perfusion defect within the mid and apical inferior,
dolinium enhancement (B,D) demonstrates a small subendocar-
iac magnetic resonance; LV  left ventricle; RV  right ventricle.n in
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858p  0.0001, respectively). Additional analyses were
performed to assess the time-varying effects of
SCOREClinical being selected in the best overall
ultivariable models for MACE of the whole
ohort and of men (Table 3), respectively. Although
tratified to the binary variable obtained from di-
hotomizing SCOREClinical at its median value, the
est overall multivariable models of the whole
ohort and of men both maintained strong associ-
tion with MACE, respectively (model LR chi-
quare test  56.72 and 23.59, both p  0.0001,
espectively).
In the 323 patients (80%) without a history of
I, ISCHEMIA() was observed in 60 patients
19%) and only ISCHEMIA was selected to form
he best overall model for MACE. However, LGE
resence, LGE mass, and percentage of LGE were
lso strong univariable predictors of MACE (LR
hi-square test  9.58, 7.14, and 8.17; hazard ratio
HR]: 4.28, 1.05, and 1.72; p  0.005, p  0.01,
nd p  0.005, respectively). These strong associ-
tions of LGE variables with MACE appeared to
omplement ISCHEMIA in patients without a
istory of MI. Adjusted to ISCHEMIA, infarct
ize measured by percentage of LGE (per 10%
ncrease of LV mass) portended to an adjusted
azard increase in MACE of 67% (adjusted LR
hi-square test  5.46, adjusted HR: 1.67; 95%
onfidence interval: 1.09–2.57, p  0.02). In
omen without a history of MI, ISCH-SCORE
nd percentage of LGE were the strongest variables
elected to form the best overall model for MACE.
djusting for known CAD variables (number of
ngiographic significant coronary arteries known
ensitivity and Speciﬁcity of ISCHEMIA to Detect Signiﬁcant
ngiographic Coronary Stenosis in Both Sexes, Women, and Men
CA () CA ()
Single-Vessel
CAD
Multiple-Vessel
CAD
(N  77)
A() 22 6 6 0
A() 7 42 24 18
% 76 88 80 100
 22)
A() 8 1 1 0
A() 2 11 8 3
% 80 92 89 100
55)
A() 14 5 5 0
A() 5 31 16 15
% 74 86 76 100
ronary angiography without signiﬁcant stenosis; CA ()  coronary angiogra-
niﬁcant stenosis; CAD  coronary artery disease; ISCHEMIA()  evidence of
sent; ISCHEMIA()  evidence of ischemia present.efore CMR, history of percutaneous coronary
ntervention, and history of MI), ISCHEMIA and
SCH-SCORE both maintained a strong associa-
ion with MACE (adjusted HR: 2.52 and 1.18;
djusted LR chi-square test  24.81 and 31.71;
oth p  0.0001, respectively). In addition, in 285
patients without any history of CAD (defined as
any history of coronary intervention, previous MI,
and significant Q waves on ECG), both ISCH-
EMIA and ISCH-SCORE were significant predic-
tors of MACE during the follow-up (HR: 17.60 and
1.32; LR chi-square test 18.34 and 26.46; both p
0.0001, respectively).
Diagnosis of signiﬁcant coronary stenosis by ISCHEMIA.
At the discretion of the referring physician, 77
patients (19%) underwent coronary angiography
within 24 months after CMR; of them, 48 patients
(61%, 12 were women) demonstrated significant
stenosis. Table 4 shows the patient numbers in
groups stratified by ISCHEMIA, presence of sig-
nificant stenosis, and single- or multiple-vessel
stenosis. ISCHEMIA detected significant stenosis
at sensitivities of 88%, 92%, and 86% for both sexes
combined, women, and men, respectively. Al-
though all cases of multiple-vessel stenosis were
detected by ISCHEMIA (100% sensitivity), single-
vessel stenosis was detected at sensitivities of 80%,
89%, and 76% for both sexes combined, women,
and men, respectively. ISCHEMIA detected sig-
nificant stenosis at specificities of 76%, 80%, and
74% in these groups, respectively.
D I S C U S S I O N
Accurate noninvasive risk stratification may be the
first of many steps that can improve the outlook of
women with CAD. Stress CMR may be ideally
suited for this purpose. We examined the prognos-
tic implications of CMR stress myocardial perfu-
sion imaging in a large single-center consecutive
cohort. We observed a strong association of ISCH-
EMIA() detected by CMR with hard cardiac
events (cardiac death or acute MI) regardless of
patient sex. CMR is thus a highly promising alter-
native noninvasive prognosticating tool that over-
comes the limitations of other techniques in imag-
ing women with suspected myocardial ischemia.
Specifically, ISCHEMIA() indicated very low
annual rates of MACE and of cardiac death in
women (0.3% and 0%, respectively), which were
similar to the observed low annual rates in men. In
contrast, ISCHEMIA() was associated with aTable 4. S
(>70%) A
Both sexes
ISCHEMI
ISCHEMI
Correct,
Women (n
ISCHEMI
ISCHEMI
Correct,
Men (n 
ISCHEMI
ISCHEMI
Correct,
CA ()  co
phy with sigmarkedly elevated HR of 56 for MACE in women.
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859In addition, we found that the segmental extent of
myocardial ischemia, quantified by ISCH-SCORE,
was the strongest multivariable predictor for
MACE in the whole cohort, in women, and in
men. These findings support consistent and robust
prognostication by CMR myocardial perfusion im-
aging regardless of patient sex.
Several factors challenge both noninvasive CAD
diagnosis and cardiac prognostication by noninva-
sive imaging in women. Compared with men,
women more often present with atypical symptoms,
have a higher burden of microvascular dysfunction,
are less likely to perform an adequate exercise test
due to comorbidities, and are more difficult to
image due to smaller heart size and breast attenu-
ation. It has also been reported that varying estro-
gen levels may cause digitalis-like false positivity on
stress ECG testing (18). These factors, either alone
or in combination, may make exercise ECG, stress
nuclear scintigraphy, or echocardiography less ac-
curate in assessing women with chest pain. These
reasons and possible underuse of stress imaging in
women may have resulted in underdetection of
CAD in women and delivery of treatment only at a
later stage of disease (19–21). CMR is appealing to
image women at risk because it provides noninva-
sive characterization of myocardial ischemia and
infarction at high spatial resolution, is relatively free
of attenuation artifacts, and does not use ionizing
radiation. The results of the current study extend
from a previous study showing high accuracy of
detecting CAD in women by CMR. Klem et al.
(22) reported a diagnostic accuracy of 87% by stress
CMR myocardial perfusion imaging in 147 women
who underwent coronary angiography.
Prognostic evidence using CMR myocardial per-
fusion imaging in CAD is growing and promising,
with several recent single-center studies all report-
ing excellent negative event-free survival rates by
CMR at up to 3 years of follow-up (4,5,23).
However, these studies did not specifically assess
the prognostic value of CMR myocardial perfusion
imaging in women. A relatively small number of
studies focus on sex differences in prognosis based
on findings of stress imaging modalities. Our results
are in accordance with other reports using nuclear
imaging, stress echocardiography, and exercise
treadmill testing. In a study of 6,173 consecutive
patients, Berman et al. (24) found an incremental
prognostic value of adenosine myocardial perfusion
single-photon emission computed tomography re-
sults over baseline data for the prediction of cardiac
death in both sexes. America et al. (25) studied a phomogeneous cohort of 453 consecutive female
patients using quantitative gated technetium-99m
tetrofosmin single-photon emission computed to-
mography. In that study, patients with a summed
stress score 14 were at risk of any cardiac event,
including death, MI, and need for revascularization.
Cortigiani et al. (26) reported additive prognostic
information from stress echocardiography over clin-
ical findings and resting wall motion score index in
8,737 patients in men and women with known and
suspected CAD. Alexander et al. (27) studied 976
women and 2,249 men undergoing exercise tread-
mill testing and cardiac catheterization. The Duke
Treadmill Score provided information beyond clin-
ical predictors of CAD and survival and performed
equally well in stratifying both sexes in prognostic
categories.
The consecutive cohort of women in our study
has a risk profile comparable to that of large
population cohorts (8% MACE during study
follow-up) (19,28). The results of our study suggest
that the prognostic value of stress CMR for MACE
including cardiac death is excellent regardless of
patient sex. Given the limitations often observed
with stress ECG, nuclear scintigraphy, and stress
echocardiography, the evidence put forth by the
current study indicates that stress CMR myocardial
perfusion imaging may be an appropriate method
for studying female patients with possible ischemia.
Study limitations. This study has several limitations.
ost important of all is the limited study power
rom a small number of MACE from a relatively
mall single-center study. However, the finding that
SCH-SCORE was one of the strongest multivari-
ble predictors consistent in each of the 3 best
verall models supports that its prognostic robust-
ess is independent of patient sex. Given the small
umber of MACE, the current experience cannot
etermine the prognostic association of ISCH-
CORE adjusted to many of the known prognostic
arkers in this clinical setting.
Our results are based on observation of a consec-
tive clinical cohort of 405 patients. We could not
lan an equivalence test because the magnitude of
he difference in observed event rates between men
nd women was unknown. As part of the clinical
orkup of this patient group, only a subset of
atients was referred for invasive angiography, and
herefore the prevalence of significant coronary
tenosis could not be determined. The lack angio-
raphic data in all patients in the cohort prohibits
ccurate determination of the negative and positive
redictive values of CMR myocardial perfusion
K
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860imaging in the detection of significant angiographic
stenosis. This limitation was patient care related
and reflects common clinical practice. Because the
main goal of the current study was the evaluation of
the prognostic value of CMR myocardial perfusion
imaging in women and men, not detection of
significant CAD, we believe that these limitations
do not nullify the observed prognostic significance.
In 15% of our patients, stress CMR was ordered
due to inconclusive findings on another noninvasive
test or presence of intermediate coronary stenosis
on angiography performed within 30 days before
the CMR study. The current pattern of CMR use
may result in a higher pretest likelihood of CAD
than if CMR had been chosen as the first-line
noninvasive test in all patients. Nevertheless, the
high negative event rates seen in the whole cohort
and in each sex attest to the high prognostic value ofCirculation 2005;112:2735–52.
1
1
1
1
1
zian V, et al. Stanalter the currently adverse outlook of women with
CAD will need to be addressed in a future study.
C O N C L U S I O N S
CMR myocardial perfusion imaging provides ro-
bust prognostication for cardiac events in both
women and men. A CMR study without evidence
of myocardial ischemia indicates a very low risk of
MACE and cardiac death in women. The prognos-
tic association of CMR myocardial perfusion imag-
ing with MACE appeared to be as strong in women
as in men, and CMR offers the advantage of
freedom from using ionizing radiation and high
image resolution.
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